Scienture Holdings, Inc. (NASDAQ:SCNX) Short Interest Down 48.4% in July

Scienture Holdings, Inc. (NASDAQ:SCNX) was the recipient of a significant decline in short interest in the month of July. As of July 31st, there was short interest totaling 1,341,608 shares, a decline of 48.4% from the July 15th total of 2,600,386 shares. Approximately 4.2% of the shares of the company are short sold. Based on an average daily trading volume, of 317,449 shares, the days-to-cover ratio is currently 4.2 days.

Hedge Funds Weigh In On Scienture

An institutional investor recently bought a new stake in Scienture stock. Virtu Financial LLC acquired a new stake in shares of Scienture Holdings, Inc. (NASDAQ:SCNX) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 89,930 shares of the company’s stock, valued at approximately $46,000. Virtu Financial LLC owned approximately 0.22% of Scienture at the end of the most recent quarter. 5.68% of the stock is currently owned by institutional investors and hedge funds.

Scienture Trading Up 0.2%

SCNX stock opened at $0.47 on Friday. The company’s 50 day moving average is $0.38 and its 200 day moving average is $0.40. The stock has a market cap of $18.93 million, a price-to-earnings ratio of -0.22 and a beta of 3.26. Scienture has a 1-year low of $0.24 and a 1-year high of $2.60.

Scienture (NASDAQ:SCNX) last announced its earnings results on Thursday, August 13th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.09) by $0.02. The company had revenue of $0.34 million for the quarter, compared to the consensus estimate of $1.96 million.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Scienture in a report on Wednesday, June 24th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $1.50.

About Scienture

Scienture Holdings, Inc engages in the provision of health services and pharmaceutical products. It focuses on addressing underserved patients and indications through novel product concepts and innovation. The company was founded on July 15, 2005 and is headquartered in Lutz, FL.